• 1 December 2026
  • 24 min 47
  • 1 December 2026
  • 24 min 47

Dhineli Perera chats to infectious diseases specialist Jane Davies about her paper on Hepatitis B. Jane outlines the new Fourth National Hepatitis B Strategy 2025–2030 and the latest recommendations aimed at eliminating hepatitis B. Jane explains the importance of population-wide testing to identify hepatitis B status, removal of accreditation requirements for antiviral prescribers, and long-term monitoring and care of people with chronic hepatitis B infection. Read the full article in Australian Prescriber.

Transcript

[Music] Welcome to the Australian Prescriber Podcast. An independent, no-nonsense podcast for busy health professionals.

I'm Dhineli Perera, your host for this episode. And today, I feel really lucky to chat with a bit of a rockstar trailblazer in the sphere of transforming care for First Nations people in the Northern Territory. Prof Jane Davies is an infectious diseases physician at Menzies School of Health Research in Darwin and a clinician researcher with a special focus in hepatitis B. Jane, together with the co-authors, Dr Marilou Capati and Dr Nicole Allard, walk us through the next steps towards the elimination of hepatitis B. A really warm welcome to you today, Jane.

Thank you. Thanks for having me.

Jane, I thought you could start us off by bringing us up to speed with a few facts about hepatitis B.

Yeah, there's some really interesting fun facts. The first thing that just blows my mind is that a third of the world's population have been infected with the hepatitis B virus, which is just huge. So, this is a huge worldwide problem. Hepatitis B in its own right as a virus is the second most potent carcinogen after tobacco. Huge impact on liver cancer risk across the world. Often you can have hepatitis B virus for a very long time and you might not have any symptoms at all. So, the only way to really know whether you have it, you don't have it, or you're protected against it from vaccination, is to have a blood test.

When you talk about the treatment for hepatitis B, can it actually cure the infection? And if not, what are we actually able to eliminate?

Great question. So, whilst lots of people are working really, really hard on achieving a cure for hepatitis B, we don't have one yet. So, the medicine that we have for treating people who are living with chronic hepatitis B is an antiviral medicine that controls the virus. So, it stops it from replicating and controls its ability to cause damage within the body, but it doesn't cure it.

Okay. So, it's like a suppression.

Yeah.

Right. Okay. So then with that in mind, what are some of the other barriers to testing, diagnosis and care for our hepatitis B population?

As I mentioned before, the asymptomatic nature, so the fact that you can feel completely normal and, unless you have had that blood test, you might not know about your hepatitis B. So, that's one barrier to people even thinking about getting a test.

Yeah, there's no trigger, right?

Yeah, that's right. And so, if you don't get that blood test, then you would never know and you would never get your diagnosis. Other barriers can be there is still stigma associated with hepatitis B on lots of levels. There shouldn't be. There's definitely no shame in having hepatitis B. It's an infection like any other, but there is still some stigma associated with that. And in some countries, there are barriers from a legal perspective and a legislative perspective in terms of attending university, for example, or certain jobs and also for certain visa conditions and things like that. So sometimes, people are worried that if they know about their infection, maybe it might prevent them from doing something or going somewhere. So that can certainly impact on people's willingness to have a test. Traditionally, hepatitis B care has often been a referral to the hospital. And so again, if people don't feel unwell, then potentially that can be logistics and cost and taking time off work and accessing a hospital setting can also make it tricky.

Right. So, there's a fairly multifaceted reason to the barriers to getting all of this under control.

Absolutely. Yeah.

And the article really touches on the prevalence of hepatitis B in Aboriginal and Torres Strait Islander people in Australia. And I wanted to know how does this compare with Australia as a whole?

Yeah. So Aboriginal and Torres Strait Islander people in Australia are disproportionately affected, as you say, and the overall prevalence for chronic hepatitis B across Australia as a whole country is quite low in worldwide terms. So, it would be around the 0.8% mark. But for Aboriginal and Torres Strait Islander people, it's significantly higher than that. And the geography of it does make a difference. So, if you look at, again Australia overall, for Aboriginal and Torres Strait Islander people, it would be around the 3.4%. But then if you look at the Northern Territory, for example, it would be somewhere between 2% and 12%, depending on which area. And Northern Australia in general is disproportionately impacted from a prevalence perspective in terms of Aboriginal and Torres Strait Islander people.

So, there's definitely part of the gap that needs to be closed in terms of treatment for that group of people. And so, when it comes to requesting the test, how simple is it to test for hepatitis B and what specifics need to be requested on the pathology slip? I feel like this is probably the area that most clinicians that are not well versed in hepatitis B would struggle [with], would scratch their heads and go, "Okay, that's great, but what am I asking and how do I interpret this?"

Yeah, absolutely. The good news is that it's really simple. So, it just takes one gold top serum blood tube when you're requesting blood. And essentially, you need to ask, in the first instance, for 3 elements of serological tests. So, there's the hepatitis B surface antigen, the hepatitis B surface antibody, and the hepatitis B core antibody. And if you have those 3 pieces of information, you can actually interpret that to have a hep B status for all individuals.

Wonderful. For all the listeners, there's a really great table in Jane's article, which clearly lists it out in terms of interpretation. I do love it. I will be referring to it myself in my own practice because personally I find a lot of the antigen antibody results so confusing when they come back. I find it difficult to interpret and I'm sure I'm not alone with that. So please do refer to that really great table. Moving on to your comment then, Jane, about risk-based testing in your paper. Why do you think risk-based testing is really not effective enough?

I think that whenever you're adding a level of complexity in the decision making as to whether to test someone or not, and particularly when something is stigmatised and particularly when it's asking often personal questions to try to evaluate whether someone is supposedly high risk for a certain thing, that always adds multiple layers of complexity and also barrier, both from a patient and a clinician perspective. So, for something that is very preventable, is a very cheap test to do and is relatively common, and we in Australia have a high proportion of people living with chronic hepatitis B who don't know about their diagnosis and we need to know in order to prevent liver cancer and cirrhosis for those people, there's really good arguments to just take out that complexity, take out that need to ask people where they were born, about their sexual orientation, about their profession, and just test everybody once in their life. There are very good arguments to make it just as simple as possible.

Right. That definitely makes sense. And so then in the case for that universal testing, where do you propose that a patient's hepatitis B status should be recorded? So, where you have this wonderful record and you've got multiple health providers, where's the best place that you propose that we find it?

So, how we have done it in the Northern Territory is we have basically committed to every single person in a health service having their hep B status recorded on their problem list. So, on that summary that comes up in most electronic health records, because you can allocate people to one of five very clear categories. And I guess, for most people, once you know their hepatitis B status, you don't necessarily have to ever really think about that or test them again. You only then need to concentrate on the people who have chronic hepatitis B.

Right. So, that was part of that question. I was thinking, Jane, how long is that status valid for once we've got it?

Universal vaccination for hepatitis B came in in different states and territories at slightly different times. For example, in Northern Australia, it came in 1988 for Aboriginal and Torres Strait Islander people and 1990 for all children. So, for people who have been vaccinated and they have received 3 vaccines through the national programme and that's recorded now on the Australian Immunisation Register, and then you do their hep B serology and get a hep B status and they don't have chronic hepatitis B, then really they're protected through the vaccine, they don't have the infection, and so then you don't need to worry about that group of people unless they became immunosuppressed or something happened to them in the future. And so, that's an increasingly large group of people that would have been part of that universal vaccine programme. So those people are straightforward.

And then there's a group of people who have had past hepatitis B, and so they have a core antibody positive but surface antigen negative. And again, once you've done that person's status, they're not going to get hepatitis B again because they've had it and cleared it and are protected against it, unless they became immunosuppressed for some reason. So again, that group of people, you don't need to do it again. And then, you've got the people who do have hepatitis B, and obviously they need lifelong follow up. And then you've got the people who they don't have hepatitis B, but they're still vulnerable, they're not immune, so they may get it in the future. And that's really the only group of people who you would have to either vaccinate them and then they would be protected. Or if they don't want vaccination or they don't qualify for vaccination, then those people potentially in the future would need a test again.

Okay. So, it really depends on that test result in terms of the longevity of its result.

Yes.

Okay. That makes a lot more sense. Thank you for clarifying that. So then, Jane, can you walk us through the Hep B PAST programme or P-A-S-T programme and the critical enablers that would allow successful rollout elsewhere in Australia?

Yeah, sure. No worries. So, we're really excited to report that the Hep B PAST programme has been evaluated. It shows successful results. We can meet the national strategy targets using this model. And we've just also published a paper in the last couple of weeks to say that it's also cost-effective. So, the elements of it's very holistic in terms of trying to address all aspects of care. It's very much a partnership approach.

So, it really takes the whole team to deliver the model of care, but it's really based on some very simple principles and steps. The first one being that you need to know everybody's hep B status so that you can put them into those categories that we just talked about. And also, as you say, in the table in the article, so that you can have people who are protected and don't need any further follow-up, people who need to be offered vaccination, and then people who need lifelong care because they have chronic hepatitis B.

But out of your total population of your clinic or practise or cluster of clinics, the people who need lifelong follow-up, you've narrowed it down to a much smaller group of people, but you've not missed anybody because you've done it in a very systematic way. So, we call that the foundation step, and it's essentially establishing everyone's hep B status. Then when you have everyone's hep B status, you can then really focus your attention on the people who have chronic hepatitis B. The model of care is really to try to move the vast majority of that care for this chronic condition that will need lifelong follow-up into the primary care setting so that people don't need to come to the hospital. And it's thought that about 80% of care can be provided in primary care. And so, the elements around that that were part of the setup of the programme was a lot of education and capacity building.

And in the setting of the Northern Territory, that was very much focused on Aboriginal health practitioners, as well as nurses and GPs [general practitioners] within primary care. And then that primary care continual monitoring and follow-up is supported by what we call the liver one-stop shop, which goes into primary care. So, like an inreach or an outreach, depending on where you are in the country. And essentially the one-stop shop provides the bits that are more difficult to access in a primary care setting. So, access to a specialist and a prescriber, although the prescriber is no longer essential because obviously the rules have changed around prescribing antivirals and now all GPs can prescribe. But prior to very recently, you needed someone who had the specialist qualification to prescribe.

So, the one-stop shop has a prescriber. It has access to FibroScan so that you can assess someone's liver fibrosis and cirrhotic status. And it has access to ultrasound, which again is often a barrier to hepatocellular carcinoma surveillance for people with chronic hepatitis B. And then crucially, it has a trained Aboriginal health practitioner who is able to provide education for patients in their first language or their preferred language. And so, those are the key elements that work together with primary care supported by the one-stop shop. And then the third element is really continuous quality improvement cycles, basically looking at the data of who's up to date, who's had the things that they need to have on a 6 and 12 monthly basis, and feeding that data back every 6 months to the services and to the clinics and to the one-stop shop so that we're continually making sure that people are being offered the appropriate follow-up and treatment.

And so, within those 3 steps, if you put them all together, then the national strategy targets, which are moving towards elimination of hepatitis B by 2030 as per the WHO [World Health Organization] goals, we've shown that taking this approach, you can meet those targets.

It sounds so holistic and comprehensive. I really admire the way that you've thought about the different angles to address this and really that follow up and closing that loop so that there's just not that loss to care. It's so impressive. Congratulations on that, Jane.

Thank you so much. Yeah, we're really proud of it.

Yeah, you should be. You've partially addressed my next question, which was about Table 2 from your paper and the assessment of people diagnosed with chronic hepatitis B. Is there anything further from that table that you would like to add to that really comprehensive programme that you haven't already highlighted?

I guess from a clinical assessment perspective, it's really useful to think about the clinical care for the person in front of you in a few parallel streams. So, there's thinking about the virus, so the hepatitis B virus itself and all the metrics that go along with that, such as the viral load and what phase of disease someone is in. And then you separately always have to think about the liver. So, what's the liver doing? Does the person have cirrhosis or advanced fibrosis? Are there other co‑factors that are impacting on the liver such as diabetes or alcohol or other viruses? So, if you think about the virus and then you think about the liver, and then the next stream would be thinking about the broader family and social circumstances of the patient. So, in terms of contact tracing, household contacts, is everybody else in the family or any sexual partners, have they been checked and vaccinated and are they protected?

And then, I guess the fourth thing is, again, that more holistic view of social and cultural needs of the person and the access to information in their first language. So, the table tries to step through those things in terms of each time you review a person with chronic hepatitis B, there is quite a lot to get through in terms of those 4 parallel things that are interacting.

Yeah. Thank you for that. I would recommend listeners definitely review the table itself because it's really clearly listed out and encompasses all of these points that Jane has highlighted. So, although ongoing chronic hepatitis B and/or cirrhosis can seem complex, would you be happy to summarise the 3 key questions that should be addressed? For example, including where GPs could go to find local specialists to make referrals to and things like that?

Yeah, sure. So, the key questions from a patient perspective are does the person need treatment for their hepatitis B? Do they have cirrhosis? And if so, do they need HCC [hepatocellular carcinoma] surveillance and follow up from their cirrhosis perspective? In terms of access for GPs to find a local specialist, there are lots of places to look for that and lots of good resources. So, Hepatitis Australia has a programme called HepLink where you can call the national information line and liaise with someone who has information across all states and territories in order to link into services and clinical care in the area where the person may be. There's also ASHM who still have a map on their website of all the prescribers, so hep B prescribers who've done that additional specialist training.

And I believe that that is going to continue despite the change in the rules around S100 prescribing for hep B antivirals. There is the PHN [Primary Health Networks] clinical care pathways. Most places would have a hep B and hep C clinical care pathway where you could access referral information for your local area. And for GP practices that would see a significant number of patients with chronic hepatitis B, it's always really good to try to set up and develop relationships with your local prescribers and certainly through the Hep B PAST programme and also through delivery of the S100 Hep B management course in the Northern Territory, we have definitely developed those kinds of relationships with local GPs who see a fair number of patients with chronic hep B so that we can link people in rapidly when they might be concerned that they've moved into that 20% of people who need specialist care.

Wonderful. Some of these links that Jane has mentioned in the article as well. In particular, the HepLink national hepatitis information line is at the bottom of Table 2. And so finally, Jane, what changes have been made to the WHO guidelines and do our own national guidelines match these changes?

The WHO guidelines have been updated, as you say, recently and have really broadened the number of people who are recommended to be offered treatment for their hepatitis B. And so, that has expanded for a number of reasons. One, for simplicity and to remove a barrier to accessing treatment that comes along with having very complex algorithms and guidelines. Also, because they're obviously international guidelines, not everyone everywhere can access a viral load for hepatitis B easily and often it can be quite expensive in some countries. So, it's enabling people to access treatment without always having access to that technology.

And then also thinking about comorbidities. And I think increasingly people living with chronic hepatitis B are not just living with chronic hepatitis B in isolation. They often have other co-factors which may be impacting on their liver. And previously those had not been explicitly taken into consideration in guidelines. And so, things like fatty liver and diabetes and renal disease are all taken into consideration more in the new WHO guidelines.

The result of all those changes is that lots more people qualify for treatment. So, we looked at our Northern Territory population and going from around 25 to 30% currently qualifying for treatment based on the Australian national guidelines, that goes up to about 60 to 70% if you apply the new WHO guidelines. So, you're more getting to a situation where you're asking why shouldn't I offer this person treatment rather than why should I?

Yeah.

And so, our national guidelines have not got to that point yet. And at the moment they don't match the WHO guidelines, but there is a process which is ongoing, which is reviewing our national consensus statement. We don't have the final outcome of that yet, but they will be moving towards broader treatment than they currently suggest.

Wonderful. As always, Jane, there's so many more questions I could ask about this, but that's unfortunately all we've got time for today. Thank you so much for joining us.

Thanks so much for having me.

[Music]

Professor Jane Davies' article, Hepatitis B Update: Enabling Progress Towards Elimination is available on the Australian Prescriber website. The views of the hosts and guests on the podcasts are their own and may not represent Australian prescriber or therapeutic guidelines. Jane Davies is a board director for Hepatitis Australia. She has received funding from the Department of Health and Ageing and an NHMRC grant for research related to hepatitis B testing and management in First Nations people. She has received funding from the Australian CDC for Community Hepatitis B education programme and Roche for advisory meeting attendance.

Jane has been on the Hepatitis B advisory committee with WHO and ASHM [Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine] and was a working group member for the Hepatitis B Australia Consensus Statement and contributes to the ASHM Section 100 prescriber course. I'm Dhineli Perera and thanks for joining us on the Australian Prescriber Podcast.

A reminder you can claim CPD for Australian Prescriber articles and podcasts by self-reporting through your college or institution. PSA members can claim accredited CPD for articles, and RACGP members for both articles and podcasts. Visit our website for details.

 

CPD for GPs - reflective questions

  • Identify and summarise 3 key points relevant to your scope of practice.
  • Identify the key clinical learnings that may be incorporated into the clinical assessment, work-up and/or management plan for appropriate patients.
  • If relevant, would you change any of your management strategies for those patients identified by appropriate screening, examination, prescribing and investigation?

Submit answers